Omega-3 Fatty Acids as Adjunctive Treatment for Adolescents With Eating Disorders

Eating Disorder Clinical Trial

Official title:

Omega-3 Fatty Acids as Adjunctive Treatment for Adolescents With Eating Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01985178
• Other study ID #: 12345
• Status: Completed
• Phase: N/A
• Start date: October 2013
• Est. completion date: August 2016

Study information

• Verified date: April 2015
• Source: McMaster University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Eating disorders are conditions that are defined by abnormal eating habits that involve insufficient or excessive food intake. With regards to treating these disorders, there is an increasing interest in fat deprivation due to a lack of proper diet, particularly dietary fats such as polyunsaturated fatty acids. These fatty acids are essential components of the brain and are important for normal functioning of the body. Since the body cannot synthesize these fats, it has to rely completely on diet to obtain a sufficient amount. Hence, diets that lack sufficient fats or under fasting conditions, the imbalance of these fats can severely alter brain functions. The investigators want to see if these supplements are well tolerated and accepted by adolescent patients with eating disorders.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

• diagnosis of Eating Disorder, less than 18 years of age

Exclusion Criteria:

• unable to read and understand English

Related Conditions & MeSH terms

• Eating Disorder
• Feeding and Eating Disorders

Intervention

Dietary Supplement:
• Omega-3 Fatty Acid Supplement

Locations

Country	Name	City	State
Canada	McMaster Children's Hospital	Hamilton	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
McMaster University

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Severity of depressive symptoms		2 months
Primary	Dropout rate		2 months
Secondary	Rate of patients reporting side effects		2 months
Secondary	Change in weight		2 months